ICT-121: Completed Phase I enrollment

ImmunoCellular completed enrollment of 20 patients with HLA-A2 positive GBM in an open-label, U.S. Phase I trial to evaluate ICT-121. Patients will receive ICI-121 once weekly for 4 weeks followed by...